Core 4 - Genome Sequencing Core

核心 4 - 基因组测序核心

• 批准号: 10555738
• 负责人: Jens G Lohr
• 金额: $ 31.35万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-12-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10555738
• 关键词: Base Pairing; Bioinformatics; Cancer Center; Cell Count; Cells; Clinical; Code; DNA; DNA Sequencing Facility; DNA methylation profiling; DNA sequencing; Dana-Farber Cancer Institute; Data; Data Analyses; Diagnosis; Evolution; Future; Genes; Genomic Segment; Genomics; Goals; Individual; Informatics; Laboratories; Methylation; Modality; Multiple Myeloma; Mutation; Newly Diagnosed; Output; Patients; Process; Relapse; Resolution; Running; Sampling; Sampling Studies; Science; Sequence Analysis; Standardization; Subgroup; Technology; Testing; Time; Untranslated RNA; Variant; analysis pipeline; cancer genome; cancer genomics; cell free DNA; cost effective; flexibility; genome sequencing; genome-wide; improved; innovation; instrument; next generation sequencing; novel sequencing technology; sequencing platform; single cell sequencing; targeted sequencing; whole genome

Project Summary – Core 4 – Genome Sequencing Core Dana-Farber Cancer Institute Whole genome sequencing especially at single cell level is a specialized function requiring expertise, special instruments and facilities along with informatics capabilities. This function cannot be performed in individual laboratories. Single cell sequencing is also evolving rapidly and constantly improving the information capabilities, number of samples per run and data modalities per cell. There is only limited number of facilities available worldwide with such capabilities to continue to innovate. Dana Farber/Harvard Cancer Center (DF/HCC) is a major center in the US sequencing significant number of cancer genomes. DFCI is committed to continually appraising new sequencing technologies, using in-house testing wherever possible, and will use whatever future technology is most suitable and cost-effective for the applications demanded by the science pursued at the Institute. The purpose of Core 4 is to provide for comprehensive genomic sequence analyses by utilizing a state of the art ‘next generation’ sequencing platform for the sequencing of whole genome, targeted regions, methylated regions, circulating cells as well as single cells and the identification and characterization of genome- wide somatic alterations in samples detailed in all projects. We have also developed and standardized single cell and bulk sequencing for various platforms. To meet these goals we will perform whole genome sequencing and enzymatic methylation sequencing to generate genome wide somatic alterations and methylation changes with streamlined analysis pipeline from IFM/DFCI 2009 and 2020-02 study samples at diagnosis and when available at relapse (Specific Aim 1); and generate single-cell whole genome and targeted sequencing data from selected serial samples to explore clonal changes during MM evolution (Specific Aim 2). Further, the core will provide bioinformatics expertise in the management and analysis of data produced within the core to support the projects.

项目摘要 - 核心4 - 基因组测序核心Dana-Farber癌症研究所 整个基因组测序尤其是在单细胞水平上是一个专业知识的专业功能， 仪器和设施以及信息功能。此功能不能在个人中执行 实验室。单细胞测序也正在迅速发展，并不断提高信息能力， 每次运行的样本数量和每个单元格的数据方式。可用的设施数量有限 在全球范围内，具有继续创新的能力。 Dana Farber/Harvard Cancer Center（DF/HCC）是 美国的主要中心测序大量的癌症基因组。 DFCI致力于连续 评估新的测序技术，尽可能使用内部测试，并将使用任何未来 技术最适合于在 研究所。核心4的目的是通过使用状态提供全面的基因组序列分析 艺术“下一代”测序平台，用于整个基因组的测序，有针对性区域， 甲基化区域，循环细胞以及单细胞以及基因组的鉴定和表征 所有项目中详细介绍的样品中的大细小变化。我们还开发和标准化了 各种平台的单元格和批量测序。为了满足这些目标，我们将执行整个基因组测序 和酶促甲基化测序以产生基因组广泛的体细胞改变和甲基化变化 从IFM/DFCI 2009和2020-02研究样本的简化分析管道中，何时 可在继电器（特定目标1）上获得；并从 选定的串行样品以探索MM演化期间克隆变化（特定目标2）。此外，核心将 在核心内生产的数据管理和分析以支持该数据方面提供生物信息学专业知识 项目。